NUCLEAR MEDICINE & THERANOSTICS FOR MOLECULAR IMAGING & TARGETED THERAPY
Dr Aviral Singh,
Clinical Head of Theranostics and Nuclear Medicine, GenesisCare
Murdoch, Western Australia &
Consultant Nuclear Medicine Physician,
Fiona Stanley Hospital, South Metropolitan Health Service &
Royal Perth Hospital, Perth, Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | May 2026
Dr Aviral Singh is a globally renowned Nuclear Medicine Physician with special interest in Theranostics. He holds a Fellowship from the Royal Australasian College of Physicians (2024), specialist certificates in Nuclear Medicine and Radiation Protection from Germany (2019), an MSc in Nuclear Medicine from King’s College London (2005), and Doctor of Medicine and PG Diploma in Cardiology from Zaporozhye State Medical University, Ukraine.
Dr Singh is based in Perth, Western Australia since 2024 and serves as the Clinical Head of Theranostics and Nuclear Medicine at GenesisCare Australia. He is also a Consultant Nuclear Medicine Physician at Fiona Stanley and Royal Perth Hospitals, in addition to pursuing national and international consulting physician roles as Director at Infinity Theranostics.
His prior roles include fellowships at world-leading ENETS Centres of Excellence including, Zentralklinik Bad Berka, Germany and Royal North Shore Hospital, Australia, and consultant physician positions in nuclear medicine and theranostics in Australia, Germany, and UK, with leadership in clinical research and development, and additional training in intensive care and internal medicine.
Dr Singh has co-authored 50 peer-reviewed papers, contributed a book chapter on Copper-64 radiopharmaceuticals, and holds an h-index of 30. He has delivered over 40 invited lectures for prestigious clinical societies worldwide.
Dr. Singh acts as guest editor and associate editor and peer reviewer for multiple reputed nuclear medicine journals. He is an active researcher in the field of personalised nuclear oncology and is an Investigator for several Phase 1 to 4 clinical trials in the field of Theranostics.
Source: Supplied
-
Newborn screening for congenital hypothyroidism
Assoc Prof Jack is passionate about the health and wellbeing of children and adolescents, with diverse research areas including the impacts of family friendly workplace initiatives, screening and management of thyroid disorders in infants and children. She supports her First Nations colleagues on Indigenous-led research projects funded by the Medical Research Future Fund, aiming to improve the social and emotional wellbeing of First Nations Children. Through her clinical and academic roles, Assoc Prof Jack hopes to make a positive difference to the health and well-being of children and their families.
-
Metabolic phenotyping, lipidomics & bioinformatics in dementia
Dr Luke Whiley is a dementia researcher whose work focuses on understanding how the body’s metabolism, particularly the biology of fats known as lipids, influences our health throughout ageing.
His research explores how the body responds to illness, lifestyle, and environmental stress at a chemical level, and how these responses shape longterm disease risk. Using advanced blood-based measurement technologies, Dr Whiley studies thousands of small molecules at once to build a snapshot of a person’s metabolic health. By combining these measurements with data science approaches, his work identifies biological pathways that become disrupted in disease, providing insight into why some people are more vulnerable to conditions such as dementia.
-
At the frontier of human cellular neuroscience research
Associate Professor Cedric Bardy is the Director of The Laboratory for Human Neurophysiology, Genetics & Stem Cells, located at SAHMRI. South Australia.
His current research uses preclinical, patient-derived cell models to test innovative therapeutic strategies, with a current focus on Parkinson’s disease, brain cancer and childhood dementia (Sanfilippo syndrome).
His work has established a platform to facilitate the discovery and validation of treatments for brain disorders. Their research is at the frontier of human cellular neuroscience research and translational applications that benefit global public health.
